Omission of RT in elderly breast cancer patients
-
Upload
bharti-devnani -
Category
Health & Medicine
-
view
469 -
download
0
Transcript of Omission of RT in elderly breast cancer patients
![Page 1: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/1.jpg)
JOURNAL CLUB
Dr Bharti DevnaniModerator- Dr Sushma Agrawal
![Page 2: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/2.jpg)
OVERVIEW OF PRESENTATION
Disease burden overall and in elderly
Background of the study
Present study
Discussion and Review of literature
Conclusion
![Page 3: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/3.jpg)
DISEASE BURDEN (OVERALL)
GLOBOCON 2012
Perez and Brady’s Principles of Radiation Oncology
Leading cause of cancer death among females, accounting for 23 % (1.38 million) of the total new cancer cases & 14 % (458,400)of the total cancer deaths.
![Page 4: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/4.jpg)
DISEASE BURDEN IN ELDERLY
![Page 5: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/5.jpg)
WHY THIS ISSUE IS IMPORTANT
Rising incidence (particularly in elderly)
Increasing use of breast conservation surgery in elderly women
Increasing life expectancy of women :85-90 years [Western world]
Recurrence rates low (<5%) but increases with increasing duration of follow up
Radiation decreases the risk of local recurrences in these population of patients
![Page 6: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/6.jpg)
WHY AVOID RADIATION IN THESE PATIENTS??
![Page 7: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/7.jpg)
LOW RISK GROUP (AGE IS AN IMP RISK FACTOR)
Conclusion- Radiotherapy may be avoided in patients older than 65. and may be optional in women aged 56-65 years with negative nodes.
Veronesi U et al. Ann Oncol 2001;12:997–1003
![Page 8: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/8.jpg)
Survival benefit only applied if the difference in IBTR was > 10%
![Page 9: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/9.jpg)
Elderly women have fewer local recurrences.
Survival benefit only if IBTR > 10% [EBCTCG]
Tend to have estrogen sensitive tumors so tamoxifen more efficacious.
Mortality is mostly due to non-breast cancer related causes.
Half of the local recurrences can be salvaged by lumpectomy again.(Mastectomy free survival is equal)
WHY AVOID RADIATION IN THESE PATIENTS??
![Page 10: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/10.jpg)
WHY AVOID RADIATION IN THESE PATIENTS??
Availability of radiotherapy facilities
Convenience of patients
Rationalisation of RT division workload
Psychological advantages for the patient
Reducing economical burden to the patients and society.
![Page 11: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/11.jpg)
NEED OF THE PRESENT STUDY Trials (NSABP-21) had shown benefit of addition of radiotherapy to
tamoxifen in BCS patients (LR in BCS+TAM vs. BCS+RT vs. BCS+RT+TAM: 17%, 9%,3%)
CALGB Study showed at 5 years of follow up showed LR risk in RT versus no RT as 1% versus 4% (p<0.001)
Despite the low recurrence rates reported in CALGB trial, the practice changed little [Giordano SH. J Clin Oncol 30:1577-1578, 2012]
Other studies like BASO-II, German Breast Cancer Study Group included patients with younger population (45-75 years)
A need for further study in these subset of patients (elderly low risk group) mandated further studies: PRIME II
![Page 12: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/12.jpg)
MATERIALS AND METHODS
![Page 13: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/13.jpg)
Study design Phase 3 randomised controlled trial 76 specialist cancer centres and district or
regional hospitals in four countries (the UK, Greece, Australia & Serbia)
![Page 14: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/14.jpg)
Inclusion criteria
Age > 65 years T1–T2 (up to 3 cm ) N0 M0 Hormone receptor-positive Clear excision margins (≥1 mm) Hormone treatment (Adjuvant or
Neoadjuvant) Grade III / LVI but not both.
![Page 15: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/15.jpg)
Exclusion criteria
< 65 years
H/o previous in-situ or invasive breast cancer of either breast.
Women with current or previous malignant disease within the past 5 years, other than non-melanomatous skin cancer or carcinoma in situ of the cervix.
HER2 status was not recorded as this marker was not routinely assessed at the start of the trial.
![Page 16: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/16.jpg)
RT dose fractionation Conventional # of 50 Gy/ 25# Hypofractionationated RT 40Gy /15 #
allowed.(No of patients receiving a particular # not
mentioned)Boost Electrons 10-15 Gy Implant 20 Gy to 85% reference isodose)
Hormone therapyTamoxifen 20mg for 5 yrsOthers forms allowed
![Page 17: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/17.jpg)
Follow-up
Follow-up was for 10 years Consisted of annual clinic visits, examination
and mammography for at least 5 years beyond this time, either a clinic visit or a
phone call to the patients’ primary health care doctor to ascertain their health status, in addition to follow-up mammography.
![Page 18: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/18.jpg)
End points
Primary endpoint IBTR
Secondary endpoints Regional recurrence,C/L breast cancer,Distant metastases, DFS & OS
Unplanned analysis based on hormone status
![Page 19: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/19.jpg)
Statistical analysis
Based on null hypothesis
A difference in ipsilateral breast tumour recurrence of at least 3% (2% with radiotherapy and 5% without radiotherapy) at 5 years (80% power, 5% level of signifi cance)
Sample size – 588 per group
![Page 20: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/20.jpg)
RESULTS
![Page 21: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/21.jpg)
Randomization1:1
2003-2009
![Page 22: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/22.jpg)
![Page 23: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/23.jpg)
![Page 24: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/24.jpg)
IBTR
1.3 %(6) v/s 4.1%(26)P=0.002
![Page 25: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/25.jpg)
The absolute risk reduction in ipsilateral breast tumour recurrence at 5 years was 2・9% (95% CI 1・ 1–4・ 8).
The number needed to treat was calculated to be 31・ 8 (95% CI 27・ 4–55・ 0), which equates to an adjusted absolute risk reduction of 3・ 1% (95% CI 1・ 8–3・ 6)
![Page 26: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/26.jpg)
Overall survival at 5 years was identical in the two treatment groups (93.9% v/s 95% p=0.34).
At 5 years, no differences b/w treatment groups
were noted in regional recurrences, distant metastases, contralateral breast cancers, or new cancers .
Breast cancer-free survival at 5 years was 94・5% (95% CI 92・ 5–96・ 5) in women allocated to no radiotherapy and 97・ 6% (96・ 2–99・ 0) in those assigned to whole-breast radiotherapy; the diff erence was attributable mainly to IBTR.
![Page 27: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/27.jpg)
SALVAGE SURGERY
![Page 28: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/28.jpg)
SUBGROUP ANALYSIS
In women with poor oestrogen receptor status, six (9%) of 65 women allocated no radiotherapy had local recurrence compared with none of 55 women allocated to whole-breast radiotherapyp=0・ 026); however, the number of patients in this analysis is small
![Page 29: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/29.jpg)
CONCLUSION OF THIS STUDY
Postoperative whole-breast radiotherapy after breast-conserving surgery and adjuvant endocrine treatment resulted in a significant but modest reduction in local recurrence for women aged 65 years or older with early breast cancer 5 years after randomization.
However, the 5-year rate of ipsilateral breast tumor recurrence is probably low
Omission of radiotherapy may be considered for some patients with due consideration of risk
![Page 30: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/30.jpg)
DISCUSSION AND REVIEW OF LITERATURE
![Page 31: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/31.jpg)
CALGB Potter et al
Fyles et al
Italian Tinterri et al
PRIME II
No of pts 636 869 769 749 1326Year of recruitment
1994-99 1996-2004 92-2000 2001-5 2003-9
Age (yrs) >70 PM (mean 66)
>50 PM (55-75) >65
T size T1 < 3 cm T1, T2 <2.5 cm < 3 cm
Hormone receptor status
ER + + + Any +
Grade __ Gr-1,2 -- Any III/LVSI
![Page 32: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/32.jpg)
CALGB Potter et al
Fyles et al
Italian Tinterri et al
PRIME II
Arm Sx+ TamSx+Tam+RT
Sx+ Tam or AISx+Tam or AI +RT
Sx+TamSx+Tam +RT
SxSx+ RT
Sx+HTSx+HT+RT
Follow-up(Median)
10.5yrs 4.5 5.6 5 yrs 5yrs
LR 9% v/s 2% 6 v/s 2 8 v/s 1 3% v/s 1% 4 v/s 1.3%RT # 45G/25#
14G/7#50+10 40 G/16#
12.5 G/5#50 Gy10 Gy
40-50Gy10-15 Gy
SS <0.001 <0.001 0.001 0.07 0.002Hormone Tamoxifen Tam or AI Tam No Tam or AI
![Page 33: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/33.jpg)
T1NOMO70 yearsHormone
positive
![Page 34: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/34.jpg)
9% v/s 2%
![Page 35: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/35.jpg)
Time to mastectomy , distant metastasis and OS did not differ.
![Page 36: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/36.jpg)
After a median follow-up of 53 months
IBTR 3% v/s 1% (p=0.07). OS = NS diff
T-2.5 cm55-75yearsReceptor status-Any
EIC –Negative
LVI-Negative
![Page 37: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/37.jpg)
![Page 38: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/38.jpg)
![Page 39: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/39.jpg)
![Page 40: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/40.jpg)
PROGNOSTIC FACTORS FOR RECURRENCE Age Tumor size Receptor status Grade Lymph node dissection/positivity LVSI Need of a nomogram to predict local
recurrence??
![Page 41: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/41.jpg)
NCCN GUIDELINES 2015
Radiation therapy may be omitted in patients post BCS if [Category 1]: T1 Node negative => 70 years of age Hormone receptor +ve and receiving hormone
therapy
![Page 42: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/42.jpg)
CONCLUSIONS
Adjuvant endocrine treatment alone is a reasonable therapeutic option after breast conserving surgery for women with:
Age> 65-70 years Grade 1 and 2 (NA to grade III) and no LVSI Node-negative Oestrogen receptor-positive tumours (Receiving
hormone therapy) Up to 3 cm in size
[ Patient`s preference, acceptance of risk..]
![Page 43: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/43.jpg)
THANK YOU!!
![Page 44: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/44.jpg)
![Page 45: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/45.jpg)
Postoperative whole-breast radiotherapy achieved a significant but relatively small reduction in local breast recurrence at 5 years in a population of low-risk older patients with early breast cancer after breast-conserving surgery and adjuvant endocrine treatment.
Postoperative whole-breast radiotherapy after breast-conserving surgery and adjuvant endocrine treatment
resulted in a signifi cant but modest reduction in local recurrence for women aged 65 years or older with early breast
cancer 5 years after randomisation. However, the 5-year rate of ipsilateral breast tumour recurrence is probably low
enough for omission of radiotherapy to be considered for some patients.
![Page 46: Omission of RT in elderly breast cancer patients](https://reader036.fdocuments.in/reader036/viewer/2022081604/58a4d2dc1a28ab480e8b700f/html5/thumbnails/46.jpg)
HOWEVERTreatment should be individualized based on Grade LVSI Biological profile-hormone and Her-2 Proliferative index Comorbidities Patient preferences Risk benefit ratio